Advertisement
U.S. Markets closed

AbbVie Inc. (ABBV)

NYSE - Nasdaq Real Time Price. Currency in USD
197.55+1.18 (+0.60%)
At close: 04:00PM EDT
197.15 -0.40 (-0.20%)
After hours: 07:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close196.37
Open197.25
Bid197.00 x 1000
Ask198.00 x 900
Day's Range196.23 - 197.97
52 Week Range135.85 - 197.98
Volume4,713,117
Avg. Volume5,461,259
Market Cap348.94B
Beta (5Y Monthly)0.62
PE Ratio (TTM)66.29
EPS (TTM)2.98
Earnings DateOct 25, 2024 - Oct 29, 2024
Forward Dividend & Yield6.20 (3.14%)
Ex-Dividend DateJul 15, 2024
1y Target Est196.64
  • Simply Wall St.

    Should You Be Excited About AbbVie Inc.'s (NYSE:ABBV) 78% Return On Equity?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

  • Zacks

    Pharma Stock Roundup: FDA Nod to PFE, MRNA New COVID Jabs & More

    LLY's phase III study shows that tirzepatide reduces the risk of developing type II diabetes. FDA approves PFE and MRNA's updated COVID-19 vaccine.

  • Reuters

    Analysis: Ozempic on Wall Street's list for 2027 Medicare drug negotiations

    Now that the US government has negotiated prices for some Medicare program drugs effective in 2026, Wall Street analysts are betting on a 2027 list that will include Novo Nordisk's blockbuster Ozempic for diabetes and have a limited impact on Big Pharma. Other possible 2027 candidates include Pfizer's cancer drugs Ibrance and Xtandi, GSK's asthma and chronic obstructive pulmonary disease (COPD) treatment Trelegy Ellipta, Teva's Huntington's disease treatment Austedo and Abbvie's irritable bowel syndrome drug Linzess, according to five analysts as well as researchers and company executives.